- Home
- EOI vs EYPT Comparison
EOI vs EYPT Comparison
Compare EOI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- EYPT
- Stock Information
- Founded
- EOI 2004
- EYPT N/A
- Country
- EOI United States
- EYPT
- Employees
- EOI N/A
- EYPT N/A
- Industry
- EOI Finance/Investors Services
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- EOI Finance
- EYPT Industrials
- Exchange
- EOI Nasdaq
- EYPT Nasdaq
- Market Cap
- EOI 870.1M
- EYPT 741.0M
- IPO Year
- EOI N/A
- EYPT N/A
- Fundamental
- Price
- EOI $21.40
- EYPT $14.01
- Analyst Decision
- EOI
- EYPT
- Analyst Count
- EOI 0
- EYPT 0
- Target Price
- EOI N/A
- EYPT N/A
- AVG Volume (30 Days)
- EOI 83.6K
- EYPT 659.8K
- Earning Date
- EOI 01-01-0001
- EYPT 08-06-2025
- Dividend Yield
- EOI 7.19%
- EYPT N/A
- EPS Growth
- EOI N/A
- EYPT N/A
- EPS
- EOI N/A
- EYPT N/A
- Revenue
- EOI N/A
- EYPT $51,898,000.00
- Revenue This Year
- EOI N/A
- EYPT N/A
- Revenue Next Year
- EOI N/A
- EYPT N/A
- P/E Ratio
- EOI N/A
- EYPT N/A
- Revenue Growth
- EOI N/A
- EYPT 2.99
- 52 Week Low
- EOI $14.36
- EYPT $3.91
- 52 Week High
- EOI $18.88
- EYPT $14.37
- Technical
- Relative Strength Index (RSI)
- EOI 60.53
- EYPT 77.25
- Support Level
- EOI $21.17
- EYPT $11.38
- Resistance Level
- EOI $21.43
- EYPT $12.24
- Average True Range (ATR)
- EOI 0.20
- EYPT 0.74
- MACD
- EOI 0.00
- EYPT 0.13
- Stochastic Oscillator
- EOI 74.29
- EYPT 89.80
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.